文献速递免疫规划

多价KSHV样颗粒疫苗在兔中诱导高滴度中和抗体

A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits.
PubMed 文献 · Vaccine · 2019-06-11

本研究构建了包含KSHV四种关键包膜糖蛋白(gpK8.1、gB、gH/gL)的多价KSHV样颗粒(KSHV-LP),其大小形态与KSHV病毒粒子相似。兔接种佐剂化KSHV-LP后产生强糖蛋白特异性抗体,纯化的免疫球蛋白在最高测试浓度下对上皮、内皮、成纤维和B细胞系中的KSHV感染中和率达60-90%。提示KSHV-LP可作为安全有效预防性疫苗平台。

要点

  • 多价KSHV-LP疫苗包含gpK8.1、gB和gH/gL四种包膜糖蛋白。
  • 兔接种后产生强糖蛋白特异性抗体应答。
  • 纯化Ig在最高浓度下对多种细胞系中和KSHV达60-90%。

核心结论

  • KSHV-LP可诱导兔产生高滴度中和抗体,是预防性KSHV疫苗的潜在平台。

研究设计与样本

  • 研究构建并纯化了含四种KSHV包膜糖蛋白的多价KSHV样颗粒,并在兔中评估免疫原性。

主要发现

  • 纯化KSHV-LP在大小、形状和形态上与KSHV病毒粒子相似。
  • 兔接种佐剂化KSHV-LP后产生强糖蛋白特异性抗体应答。
  • 纯化免疫球蛋白在最高测试浓度下对上皮、内皮、成纤维和B细胞系中和KSHV达60-90%。

局限性

  • 尚未在对KSHV易感的动物模型中验证体内免疫保护相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kaposi sarcoma-associated herpesvirus (KSHV) is an emerging pathogen and the causative agent of multiple cancers in immunocompromised patients. To date, there is no licensed prophylactic KSHV vaccine. In this study, we generated a novel subunit vaccine that incorporates four key KSHV envelope glycoproteins required for viral entry in diverse cell types (gpK8.1, gB, and gH/gL) into a single multivalent KSHV-like particle (KSHV-LP). Purified KSHV-LPs were similar in size, shape, and morphology to KSHV virions. Vaccination of rabbits with adjuvanted KSHV-LPs generated strong glycoprotein-specific antibody responses, and purified immunoglobulins from KSHV-LP-immunized rabbits neutralized KSHV infection in epithelial, endothelial, fibroblast, and B cell lines (60-90% at the highest concentration tested). These findings suggest that KSHV-LPs may be an ideal platform for developing a safe and effective prophylactic KSHV vaccine. We envision performing future studies in animal models that are susceptible to KSHV infection, to determine correlates of immune protection in vivo.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mulama DH, Mutsvunguma LZ, Totonchy J, et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits. Vaccine. 2019. PMID: 31201053. doi:10.1016/j.vaccine.2019.04.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。